The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is a huge mover today! About 3.15M shares traded hands. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has risen 105.84% since March 7, 2016 and is uptrending. It has outperformed by 98.24% the S&P500.
The move comes after 6 months positive chart setup for the $2.72B company. It was reported on Oct, 10 by Barchart.com. We have $19.23 PT which if reached, will make NASDAQ:ARIA worth $1.01 billion more.
Analysts await Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) to report earnings on November, 1. They expect $-0.20 earnings per share, up 31.03% or $0.09 from last year’s $-0.29 per share. After $0.57 actual earnings per share reported by Ariad Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -135.09% negative EPS growth.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Ratings Coverage
Out of 5 analysts covering Ariad Pharmaceuticals (NASDAQ:ARIA), 4 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 80% are positive. Ariad Pharmaceuticals has been the topic of 9 analyst reports since August 7, 2015 according to StockzIntelligence Inc. JP Morgan maintained Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Friday, August 7 with “Neutral” rating. SunTrust initiated it with “Buy” rating and $22 target price in Wednesday, October 5 report. On Monday, September 26 the stock rating was initiated by Leerink Swann with “Outperform”. The stock has “Underweight” rating given by Barclays Capital on Wednesday, May 11. The firm earned “Buy” rating on Wednesday, October 5 by Suntrust Robinson. The rating was maintained by Barclays Capital on Friday, July 29 with “Underweight”. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The company was initiated on Tuesday, January 19 by Barclays Capital.
According to Zacks Investment Research, “Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.”
Insitutional Activity: The institutional sentiment increased to 1.4 in Q2 2016. Its up 0.73, from 0.67 in 2016Q1. The ratio improved, as 19 funds sold all Ariad Pharmaceuticals, Inc. shares owned while 44 reduced positions. 30 funds bought stakes while 58 increased positions. They now own 131.89 million shares or 0.58% less from 132.66 million shares in 2016Q1.
Family Mngmt Corporation accumulated 179,515 shares or 0.75% of the stock. Dynamic Mgmt holds 188,768 shares or 0.16% of its portfolio. Blackrock Investment Management accumulated 0.01% or 664,847 shares. Us Savings Bank De has invested 0% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Commerzbank Aktiengesellschaft Fi accumulated 0.03% or 629,194 shares. Ameriprise Fincl, a Minnesota-based fund reported 222,952 shares. Alliancebernstein L P owns 476,585 shares or 0% of their US portfolio. First Advsrs L P has 0% invested in the company for 65,108 shares. Elk Creek Prns Ltd Liability Corporation reported 2.05M shares or 1.1% of all its holdings. Principal Financial Grp Inc Incorporated last reported 0% of its portfolio in the stock. Pdt Partners Ltd holds 0.36% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) for 618,187 shares. Bancorp Of New York Mellon, a New York-based fund reported 1.04 million shares. Consonance Capital L P has 8.85M shares for 9.25% of their US portfolio. Seven Eight Capital Ltd Co holds 15,800 shares or 0.04% of its portfolio. Nationwide Fund Advsr holds 156,798 shares or 0.01% of its portfolio.
Insider Transactions: Since April 22, 2016, the stock had 1 buy, and 12 insider sales for $3.87 million net activity. CLACKSON TIMOTHY P sold 25,000 shares worth $262,500. $626,039 worth of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) was sold by LAVIDAS ATHANESE on Monday, June 13. Radaelli Massimo had sold 108,569 shares worth $896,135. 26,990 shares with value of $199,996 were bought by Panayiotopoulos Paris on Thursday, May 12.
More news for Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) were recently published by: Prnewswire.com, which released: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on October 07, 2016. Forbes.com‘s article titled: “ARIAD Pharmaceuticals Reaches Analyst Target Price” and published on September 15, 2016 is yet another important article.
ARIA Company Profile
ARIAD Pharmaceuticals, Inc. (ARIAD), incorporated on April 12, 1991, is an oncology company. The Firm is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.